Record Details

Formation of site and conformation specific antibodies to centchroman, a new non-steroidal contraceptive drug

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Formation of site and conformation specific antibodies to centchroman, a new non-steroidal contraceptive drug
 
Creator Srivastava, Apurva K
Grover, P K
 
Description 216-226
Centchroman [Ormeloxi fene, 3,4-trans-2,
2-dimethyl-3-phenyl-4-(p-pyrrolidino ethoxy)phenyl-7
-methoxy-chroman (2a)] is a new non steroidal oral contraceptive for women. In
an attempt to develop sensitive immunoassay to measure centchroman
concentration in biological fluids, we describe production of antibodies
against four hapten derivatives of centchroman, and evaluation of efficacy of
these antibodies in developing sensitive and specific immunoassay of centchroman.
Antigens were made by coupling four hapten derivatives, 3,4-trans-2,2-dimethyl-3-phenyl-4-(p-pyrrolidinoethoxy)
phenyl-7-carboxymethoxyl-chroman (2c), 3,4-trans-2,2-dimethyl-3-phenyl-4-(p-succinoylethoxy)phenyl-7-methoxychroman
(3a), 3, 4-trans- 2,2-dimethyl-3-(m-hydroxyl)phenyl-4-(p-pyrro-lidinoethoxy)phenyl-7-methoxychroman

(5a), and 3,4-trans-2,2-dimethyl-3
-phenyl-4-(3'-amino,4' -pyrrolidinoethoxy) 
phenyl-7-methoxy-chroman (6a), to bovine serum albumin (BSA). Three
enzyme tracers, made by coupling centchroman derivatives (2c, 3a, and 5a) to peroxidase
(HRP), were utilized to monitor four antisera. Four homologous and heterologous
enzyme immunoassay formats were developed and specificity of each antiserum was
analyzed against anticipated metabolite of centchroman. Antiserum raised
against centchroman derivative (6a) was found to be most specific, showing
 
Date 2013-07-16T08:35:18Z
2013-07-16T08:35:18Z
2000-08
 
Type Article
 
Identifier 0975-0959 (Online); 0301-1208 (Print)
http://hdl.handle.net/123456789/19825
 
Language en_US
 
Rights CC Attribution-Noncommercial-No Derivative Works 2.5 India
 
Publisher NISCAIR-CSIR, India
 
Source IJBB Vol.37(4) [August 2000]